Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Intensity Therapeutics, Inc. ( (INTS) ) is now available.
On March 5, 2026, Intensity Therapeutics, Inc. received formal notice from Nasdaq that it had regained compliance with the exchange’s minimum bid price rule after its shares closed at or above $1.00 for 10 consecutive trading days from February 19 through March 4, 2026. The decision closed a deficiency process that began with Nasdaq warnings in June and December 2025, when the stock had traded below the required $1.00 threshold.
The company disclosed on March 6, 2026 that the bid-price issue was resolved, removing an immediate risk of potential delisting from the Nasdaq Capital Market. Restored compliance helps stabilize Intensity’s market standing at a critical time in its late-stage oncology development programs, supporting continued access to public equity markets and providing reassurance to investors and partners monitoring its clinical and regulatory progress.
The most recent analyst rating on (INTS) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Neutral.
The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, and material cash burn indicating continued reliance on external funding). Technicals also weigh on the score with bearish trend signals (below short-term moving averages and negative MACD). Valuation is neutral-to-weak because a negative P/E limits comparability and there is no dividend yield support.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies using its proprietary non-covalent conjugation and DfuseRx℠ technology platforms. Its lead investigational product, INT230-6, combines cisplatin, vinblastine sulfate and a diffusion enhancer for direct tumor injection, with ongoing Phase 2 and Phase 3 trials in soft tissue sarcoma and breast cancer.
The company’s approach aims to saturate tumors with cytotoxic agents, trigger rapid local tumor cell death and elicit an adaptive immune response without the systemic immunosuppression typical of chemotherapy. Intensity has completed two clinical studies involving more than 200 patients and is expanding its pipeline through collaborations such as a Phase 2/3 program with the Swiss Cancer Group in triple-negative breast cancer.
Average Trading Volume: 73,723
Technical Sentiment Signal: Sell
Current Market Cap: $19.56M
See more insights into INTS stock on TipRanks’ Stock Analysis page.